ClinicalTrials.gov
public full text
Public Domain
PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
An open-label, non-randomized, two-stage, multicenter study evaluating clinical efficacy, safety and pharmacokinetics of PQR309 in patients with relapsed or refractory Primary Central Nervous System Lymphoma (PCNSL).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms#1096360
- Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)#857700
- A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies#916791
- Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma#1372731
- Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach#981516
Record · ID 1365570
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive